Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure

 
• By Alaric DeArment

After the 14 March announcement that the IL-36R agonist failed in an acne study, it appears to have better chances in generalized pustular psoriasis, an underserved orphan indication where the target is already validated.

AnaptysBio may have a better shot at a rarer skin condition with imsidolimab after acne trial failure • Source: Shutterstock

More from Dermatological

More from Therapy Areas